Navigation Links
Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Date:10/30/2012

SAN DIEGO, Oct. 30, 2012 /PRNewswire/ -- Thesan Pharmaceuticals announced the closing of a $16M Series A financing, co-led by Novo Ventures and Novartis Venture Funds.  The company will focus on the development of novel approaches for the treatment of dermatological disorders. The lead drug candidate is a topically-applied new chemical entity expected to enter the clinic in 2013.

"For many years, drug development in the dermatology field has been dominated by old drugs just re-formulated into more cosmetically appealing foams, gels or lotions," said Gordon Foulkes, Thesan's Executive Chairman and CEO. "Thesan's mission is to develop new chemical entities with novel mechanisms of action in order to substantially improve treatment outcomes for patients with a variety of dermatological diseases." 

The company's first products have been licensed from the University of California, Irvine (UCI). The products have been developed in the laboratory of Professor Daniele Piomelli, who is Louise Turner Arnold Chair of Neurosciences at UCI and the Director of Drug Discovery and Development at the Istituto Italiano di Tecnologia (IIT), Genoa, Italy.  

"We are very pleased to be part of the investor syndicate behind Thesan," said Peter Bisgaard, Partner at Novo Ventures. "We believe Professor Piomelli's work offers a unique opportunity for developing a completely new class of anti-inflammatory agents, which can be moved rapidly into clinical development. Further, we look forward to working with Professor Piomelli and Thesan management to build the pipeline of future candidates."

"This is an extremely exciting opportunity to move toward the clinic the first technology born from the long-standing international collaboration between UCI and the IIT," said Professor Piomelli. "Our collaboration to develop therapeutic candidates has been validated by our ability to attract such a strong management team and group of investors to further commercialize our laboratories' efforts."

"A novel mechanism of action with dramatic efficacy, coupled with such solid chemistry is a great starting point for the formation of a new company," said Giovanni Ferrara, Venture Partner at Novartis Venture Funds.  "Combined with a world class team, it made for a compelling investment." 

In connection with the financing, Peter Bisgaard and Tiba Aynechi from Novo, as well as Giovanni Ferrara and Henry Skinner from Novartis have joined the company's Board, along with Dr. Howard Welgus, former VP R&D for Dermatology/Inflammation at Pfizer.  

About Thesan Pharmaceuticals, Inc.

Thesan is a newly formed, venture capital-funded biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions. For more information visit:  www.ThesanPharma.com

About Novo Ventures

Novo is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. It was established in 1999 to manage the assets of the foundation and actively make investments on its behalf. Novo Ventures focuses on life sciences venture capital, and is active in both Europe and North America. The firm has four partners in Copenhagen, one in London and three in San Francisco. With an evergreen structure, it annually invests approximately $100M in venture capital into private life sciences companies. For more information, visit: www.novo.dk

About Novartis Venture Funds

Founded in 1996, the Novartis Venture Funds currently manage over $800 million in committed capital. As a financially driven corporate life science investor, the Novartis Venture Funds invest in those companies which have the potential to address significant unmet medical needs critical to patient care. The Novartis Venture Funds' team of ten investment professionals located in Basel Switzerland and Cambridge, MA brings together extensive expertise in the biotechnology, pharmaceutical and venture capital industries. For more information, visit: www.venturefund.novartis.com

About UCI

Located in the heart of Orange County, UCI is among the fastest-growing University of California campuses, is a member of the prestigious Association of American Universities (AAU), and is consistently ranked among the nation's best universities, public and private.  The Office of Technology Alliances at UCI manages over 900 active university inventions and has licensed founding technologies to more than 50 startup companies.

About IIT

The Istituto Italiano di Tecnologia is a private law Foundation jointly established by the Ministry of Education, University and Research and the Ministry of Economy and Finance, with the aim of promoting excellence in both basic and applied research and to facilitate the development of the national economy. IIT's total staff is comprises of over 1000 individuals. In Genoa, the collaborating departments include Robotics ("Robotics, Brain and Cognitive Sciences and "Advanced Robotics"), "Neuroscience and Brain Technologies; "Drug Discovery and Development" and Nanotechnology.   

Contact:
J. Gordon Foulkes, Ph.D.
Chairman and Chief Executive Officer
Thesan Pharmaceuticals, Inc.
info@thesanpharma.com


'/>"/>
SOURCE Thesan Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Reschedules Its Third Quarter 2012 Financial Results Webcast And Conference Call To November 2, 2012 Due To Hurricane Sandy
2. Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
3. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
4. Jazz Pharmaceuticals Announces Date to Release Third Quarter 2012 Results
5. Watson Announces Sale of Rugby OTC Product Trademark and Assets to Major Pharmaceuticals, a division of The Harvard Drug Group, LLC
6. Del Mar Pharmaceuticals Expands Collaboration with Guangxi Wuzhou Pharmaceutical Company
7. Webcast Alert: Isis Pharmaceuticals Third Quarter 2012 Financial Results Conference Call
8. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
9. Access Pharmaceuticals Announces Private Placement Financing
10. Desitin Pharmaceuticals selecciona Veeva CRM, solución basada en la nube
11. Desitin Pharmaceuticals entscheidet sich für das cloudbasierte Veeva CRM zur Unterstützung seiner Expansion auf den britischen Markt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , February 5, 2016 Site ... Today, VoicePower Ltd - The Speech Recognition People, announced their latest ... to improve patient care, reduce turnaround times and to save the ... ,- VoicePower client since 2013 Challenge: --> ... --> - Six doctors ,- Wirral CCG ,- VoicePower ...
(Date:2/4/2016)... , Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... for structural heart disease and critical care monitoring, announced ... repurchase (ASR) agreement with Morgan Stanley & Co. LLC ... repurchase is part of the Company,s previously authorized program ... common stock.  --> ...
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of ... for this weekend’s Big Game. Take the stress out of your party preparation – ... guests happy at every stage of the game. , “The key to hosting a ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to ... a complete range of oral health care, including general dentistry, cosmetic treatments, periodontics, ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June 9-10, Las ... continuing medical education (CME) event presented by the Association for Comprehensive Care in ... for ACCORD, whose mission is to provide education, tools, and resources to primary ...
Breaking Medicine News(10 mins):